Intellia Therapeutics is a biotechnology company focused on developing innovative therapies using CRISPR gene-editing technology. Founded in 2014, the company aims to treat genetic diseases by precisely modifying genes within a patient's cells. Their approach has the potential to provide long-lasting solutions for conditions that currently have limited treatment options. The company is based in Cambridge, Massachusetts, and collaborates with various research institutions and pharmaceutical companies to advance its programs. Intellia's pipeline includes treatments for diseases such as sickle cell disease and beta-thalassemia, showcasing their commitment to addressing significant unmet medical needs through cutting-edge science.